Your browser doesn't support javascript.
loading
Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough?
Ganesan, Saravanan; Mathews, Vikram; Vyas, Neha.
Afiliação
  • Ganesan S; Department of Haematology, Christian Medical College, Vellore, India.
  • Mathews V; Department of Haematology, Christian Medical College, Vellore, India.
  • Vyas N; Division of Molecular Medicine, St. John's Research Institute, SJNAHS, Bengaluru, India.
Int J Cancer ; 150(9): 1401-1411, 2022 05 01.
Article em En | MEDLINE | ID: mdl-34921734
Acute myeloid leukemia (AMLs), as the name suggests, often develop suddenly and are very progressive forms of cancer. Unlike in acute promyelocytic leukemia, a subtype of AML, the outcomes in most other AMLs remain poor. This is mainly attributed to the acquired drug resistance and lack of targeted therapy. Different studies across laboratories suggest that the cellular mechanisms to impart therapy resistance are often very dynamic and should be identified in a context-specific manner. Our review highlights the progress made so far in identifying the different cellular mechanisms of mutation-independent therapy resistance in AML. It reiterates that for more effective outcomes cancer therapies should acquire a more tailored approach where the protective interactions between the cancer cells and their niches are identified and targeted.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Leucemia Promielocítica Aguda Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Leucemia Promielocítica Aguda Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article